Janus Henderson Group PLC Has $16.67 Million Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Janus Henderson Group PLC decreased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 157,833 shares of the medical equipment provider’s stock after selling 1,644 shares during the period. Janus Henderson Group PLC owned about 0.08% of Zimmer Biomet worth $16,672,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in ZBH. Stonebridge Financial Group LLC acquired a new position in Zimmer Biomet in the fourth quarter worth approximately $25,000. Accredited Wealth Management LLC acquired a new position in Zimmer Biomet in the fourth quarter worth approximately $36,000. Kentucky Trust Co acquired a new position in Zimmer Biomet in the fourth quarter worth approximately $39,000. OFI Invest Asset Management acquired a new position in Zimmer Biomet in the fourth quarter worth approximately $40,000. Finally, Dunhill Financial LLC increased its holdings in Zimmer Biomet by 86.6% in the fourth quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider’s stock worth $47,000 after buying an additional 206 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ZBH shares. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Wells Fargo & Company lowered their price target on Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 6th. JPMorgan Chase & Co. lowered their price target on Zimmer Biomet from $128.00 to $105.00 and set an “overweight” rating on the stock in a report on Tuesday, May 6th. Canaccord Genuity Group lowered their price target on Zimmer Biomet from $115.00 to $101.00 and set a “hold” rating on the stock in a report on Monday. Finally, Robert W. Baird lowered their price target on Zimmer Biomet from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $113.45.

Zimmer Biomet Stock Up 1.4%

Shares of ZBH stock opened at $96.68 on Friday. The stock has a market cap of $19.13 billion, a P/E ratio of 21.73, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a one year low of $89.92 and a one year high of $122.17. The stock has a fifty day moving average price of $103.62 and a 200 day moving average price of $105.92. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $1.91 billion during the quarter, compared to analysts’ expectations of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. Zimmer Biomet’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same period last year, the business earned $1.94 earnings per share. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were issued a dividend of $0.24 per share. The ex-dividend date was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.99%. Zimmer Biomet’s payout ratio is presently 21.24%.

Insider Transactions at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This trade represents a 14.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.39% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.